Accelerating the adoption of recombinant antibodies

The FC3R aims to replace the use of antibodies of animal origin, which present both ethical and scientific robustness problems (variability, lack of reproducibility, etc.). The antibodies most commonly used on French histology platforms have been targeted as a priority. In partnership with the Association Française d'Histotechnologie (AFH) and antibody suppliers, a pilot study was carried out to characterise the performance of alternative recombinant antibodies and share the results with the scientific community.